Bioforce’s Prostasan is second product to be approved traditional medicine by UK’s MHRA

GHENT, NY – Bioforce USA announces that its A. Vogel Prostasan (saw palmetto capsules) is the second herbal supplement to be approved by the Medicines and Healthcare products Regulatory Agency in the U.K. under the European Directive on traditional herbal medicine products. In November 2006, Bioforce’s Arnica Rub (called Atrogel Arnica gel in the E.U.) was the first product that met assured standards of quality, safety and patient information.

“The MHRA approval is an outstanding example of an herbal product available to U.S. consumers that has passed rigorous regulatory standards to ensure quality, safety and efficacy, which are the norm in Europe,” says Eileen Sheets, managing director of Bioforce USA. “With Prostasan following Arnica Rub, Bioforce continues to set examples of superior quality with this type of formal approval and recognition.”

According to Janyn Tan, managing director of Bioforce UK, this certification opens up opportunities to reach a mass audience. The indication for Prostasan is “for the relief of lower urinary tract symptoms in men who have a confirmed diagnosis of benign prostatic hypertrophy” or “for an enlarged prostate,” wording that can now appear on the packaging and promotional material. “This is exactly what Saw Palmetto is so popular for,” she says, “so the effect of the license will be to introduce the herb to a far wider audience now its indication can be highlighted in-store. With the strong indication that Prostasan now bears, it will help to attract new customers to herbal medicines and increase footfall to healthfood stores.”

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.